Dorsal horn NK1-expressing neurons control windup of downstream trigeminal nociceptive neurons.
Windup is a progressive, frequency-dependent increase in the excitability of trigeminal and spinal dorsal horn wide dynamic range (WDR) nociceptive neurons to repetitive stimulation of primary afferent nociceptive C-fibers. Superficial dorsal horn neurokinin 1 receptor (NK1R)-expressing neurons were recently shown to regulate sensitization of WDR nociceptive neurons through activation of a defined spino-bulbo-spinal loop. However, the windup of WDR nociceptive neurons was not regulated through this loop. In the present study, we sought to identify the alternative circuit activated by dorsal horn NK1Rs that mediates WDR neuron windup. As a model we used the rat spinal trigeminal nucleus, in which the subnucleus oralis (Sp5O) contains a pool of WDR neurons that receive their nociceptive C-input indirectly via interneurons located in the medullary dorsal horn (MDH). First, we found that intravenous injection of NK1R antagonists (SR140333 and RP67580) produced a reversible inhibition of Sp5O WDR neuron windup. Second, we anatomically identified in the MDH lamina III a subpopulation of NK1R-expressing local interneurons that relay nociceptive information from the MDH to downstream Sp5O neurons. Third, using microinjections of NK1R antagonists during in vivo electrophysiological recordings from Sp5O WDR neurons, we showed that WDR neuron windup depends on activation of NK1Rs located in the MDH laminae I-III. We conclude that, in contrast to central sensitization that is controlled by a spino-bulbo-spinal loop, Sp5O WDR neuron windup is regulated through a local circuit activated by MDH lamina III NK1Rs.
Coste
Jérôme
J
Inserm E216, Neurobiologie de la douleur trigéminale, Faculté de Chirurgie Dentaire, 11 Boulevard Charles de Gaulle, 63000 Clermont-Ferrand, France Univ. Clermont1, Clermont-Ferrand F-63000, France CHU Clermont-Ferrand, Clermont-Ferrand F-63000, France.
Voisin
Daniel L
DL
Miraucourt
Loïs S
LS
Dallel
Radhouane
R
Luccarini
Philippe
P
D000344:Afferent Pathways / Q000166:cytology / Q000378:metabolism*; D000818:Animals; D008297:Male; D036421:Nerve Fibers, Unmyelinated / Q000378:metabolism / Q000648:ultrastructure; D009434:Neural Pathways / Q000166:cytology / Q000378:metabolism; D064729:Neurokinin-1 Receptor Antagonists; D009475:Neurons, Afferent / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D009619:Nociceptors / Q000166:cytology / Q000378:metabolism*; D010146:Pain / Q000378:metabolism* / Q000503:physiopathology; D010880:Piperidines / Q000494:pharmacology; D020671:Posterior Horn Cells / Q000187:drug effects / Q000378:metabolism*; D017729:Presynaptic Terminals / Q000378:metabolism / Q000648:ultrastructure; D011812:Quinuclidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018040:Receptors, Neurokinin-1 / Q000378:metabolism*; D013373:Substance P / Q000378:metabolism; D009435:Synaptic Transmission / Q000502:physiology; D014275:Trigeminal Caudal Nucleus / Q000166:cytology / Q000378:metabolism*; D014276:Trigeminal Nerve / Q000166:cytology / Q000378:metabolism; D014278:Trigeminal Nuclei / Q000166:cytology / Q000378:metabolism
D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines; D011812:Quinuclidines; D018040:Receptors, Neurokinin-1; C085215:SR 140333; D013373:Substance P